Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trialLudwig Kappos, Stephen L. Hauser, David Li et al.|The Lancet|2011Cited by 743
Ofatumumab versus Teriflunomide in Multiple SclerosisStephen L. Hauser, Ludwig Kappos, Amit Bar‐Or et al.|New England Journal of Medicine|2020Cited by 706
Clinical Features of Parkinson Disease Patients With Homozygous Leucine-Rich Repeat Kinase 2 G2019S MutationsLianna Ishihara, Fayçal Hentati, Ryan J. Uitti et al.|Archives of Neurology|2006Cited by 103
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease familiesLianna Ishihara, Fayçal Hentati, Rachel A. Gibson et al.|Movement Disorders|2006Cited by 92